Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Acquired Resistance
14%
Advanced Breast Cancer
100%
Adverse Event Rates
14%
Adverse Events
14%
Aromatase Inhibitors
100%
Bone-only Disease
14%
Breast Cancer Susceptibility
14%
Breast Tumor
14%
Clinical Benefit Rate
42%
Clinical Toxicity
14%
Co-sensitization
14%
Confidence Interval
71%
Daily Dose
14%
Deprivation Therapy
14%
Estradiol
100%
Estradiol Therapy
100%
Estrogen Deprivation
28%
Flare Reaction
28%
Fluorodeoxyglucose F18
28%
Group 11
14%
High Dose
100%
High Risk
14%
Hormone Receptor-positive
100%
Hormone Receptor-positive Breast Cancer
28%
Inhibitor Resistant
100%
Laboratory Toxicity
14%
Metabolic
14%
Metastatic Breast Cancer
14%
Partial Response
14%
Phase III Clinical Trial
14%
Positive Predictive Value
14%
Positron Emission Tomography-computed Tomography (PET-CT)
14%
Postmenopausal Women
14%
Predictive Properties
14%
Progression-free Survival
28%
Quality of Life
14%
Radiological Assessment
14%
Randomized Trial
14%
Resistance to Aromatase Inhibitor
14%
Response Rate
14%
Sensitive Diseases
14%
Serious Adverse Events
14%
Serum Estradiol
100%
Stable Disease
28%
Time to Treatment Failure
14%
Toxicity Reaction
14%
Treatment Efficacy
14%
Trial Registration
14%
Tumor
14%
Tumor Cells
14%
Tumor Response
14%
Medicine and Dentistry
Adverse Event
30%
Aromatase Inhibitor
100%
Bone Lesion
10%
Breast Cancer
100%
Clinical Trial
10%
Diethylstilbestrol
100%
Diseases
40%
Drug Megadose
100%
Fluorodeoxyglucose F 18
20%
Hormone Receptor
100%
Low Drug Dose
100%
Metastatic Breast Cancer
10%
Neoplasm
20%
Oral
100%
Positron Emission Tomography-Computed Tomography
10%
Postmenopause
10%
Progression Free Survival
20%
Quality of Life
10%
Survival Time
10%
Time to Treatment
10%
Tumor Cell
10%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
30%
Aromatase Inhibitor
100%
Bone Lesion
10%
Breast Cancer
100%
Clinical Trial
10%
Diethylstilbestrol
100%
Diseases
40%
Fluorodeoxyglucose F 18
20%
Hormone Receptor
100%
Metastatic Breast Cancer
10%
Neoplasm
30%
Progression Free Survival
20%
Survival Time
10%
Tablet
20%